Sean Christensen
Director of Investor Relations
Replay available
DexCom, Inc. (NASDAQ: DXCM) Q2 2025 earnings conference call, held 2025-07-30. Replay captured from the company's public earnings webcast.

Director of Investor Relations
Chairman and Chief Executive Officer
Chief Financial Officer
President and Incoming Chief Executive Officer
Analyst, Bank of America
Analyst, Wells Fargo
Analyst, JPMorgan Chase
Analyst, Citibank
Analyst, Jefferies
Analyst, UBS
Analyst, Goldman Sachs
Analyst, Raymond James
Analyst, Piper Sandler
Analyst, DTIG
Analyst, Redburn Atlantic
Analyst, Oppenheimer
Analyst, RBC
Analyst, Wolf Research
Analyst, TD Cowan
Analyst, William Blair
Analyst, Canaccord Genuity
and investor relations. Mr. Christensen, you may begin. Thank you, operator, and welcome to Dexcom's second quarter 2025 earnings call. Our agenda begins with Kevin Sayre, Dexcom's chairman and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jeremy Sylvain, our chief financial officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our second quarter 2025 performance on the Dexcom Investor Relations website on the events and presentations page. With that, let's review our safe harbor statement. Some of the statements we will make on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included on this call are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this call or to conform these...